Dexilant generic
Dexilant is an anti-heartburn drug developed and owned by Takeda Pharms Usa. This drug, containing the active ingredient dexlansoprazole, was first authorized for market use on January 30, 2009. The drug is available in delayed release capsules for oral consumption. To date, Dexilant holds 18 patents, four of which have already expired.
When will Dexilant generic be available?
The patent that primarily influences when Dexilant generic will be available is US9233103 which is titled 'Methods for treating heartburn, gastric bleeding or hemorrhage in patients receiving clopidogrel therapy'. It is significant as it's the last one to expire, on March 05, 2032. Therefore, the release of generic versions of Dexilant will not likely be possible until after that date.
Dexilant uses
Dexilant is primarily utilized in the treatment of heartburn linked with non-erosive gastroesophageal reflux disease (GERD). The effectiveness of the drug comes from dexlansoprazole, its active ingredient, which provides relief and healing in various situations such as treatment for symptomatic non-erosive GERD, and for the healing of all grades of erosive esophagitis (EE) for up to 8 weeks; maintenance of the healing of erosive esophagitis (EE) for up to 6 months.
Dexilant patent expiration
Dexilant possesses various patents related to its formulation, the methods of its production, and its uses. The patents have different expiry dates, with the latest one, patent US9233103, expected to expire on March 05, 2032. As a result, Dexilant generic will not be available until after this date. Below is the detailing of the patent: